Addressing conceptual pillars of restrictions on gonadotropin-releasing hormone analogs for transgender adolescents.

In recent years, legislative, administrative, and judicial restrictions on transgender and gender-diverse adolescents to access transition-related health care have escalated internationally. To date, 27 states have adopted legislation restricting or banning some form of transition-related health care for transgender and gender-diverse adolescents. Proponents of these restrictions, including the lawmakers who introduce them, argue that this field of care, and specifically gonadotropin-releasing hormone analogs are experimental and should therefore be legislatively restricted to protect children. Concerns are also raised that transgender and gender-diverse adolescents lack the capacity to make decisions regarding their medical care or identity. However, such claims are destabilized by compelling evidence, suggesting a discriminatory double-standard applied to the use of gonadotropin-releasing hormone analogs in regimens of care associated with affirming the identities of adolescents from a marginalize population. (PsycInfo Database Record (c) 2026 APA, all rights reserved).